Checkpoint inhibitor induced esophagitis with documented resolution on infliximab

Acero Brand, 2018, Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab, J. Immunother. Cancer, 6, 22, 10.1186/s40425-018-0332-z Boike, 2017, Severe esophagitis and gastritis from nivolumab therapy, ACG Case Rep. J., 4, e57, 10.14309/crj.2017.57 Brahmer, 2018, Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline, J. Clin. Oncol., 36, 1714, 10.1200/JCO.2017.77.6385 Grover, 2018, Gastrointestinal and hepatic toxicities of checkpoint inhibitors: algorithms for management, Am. Soc. Clin. Oncol. Educ. Book, 38, 13, 10.1200/EDBK_100013 Horisberger, 2018, A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy, J. Immunother. Cancer, 6, 156, 10.1186/s40425-018-0481-0 Johncilla, 2020, Morphological spectrum of immune check-point inhibitor therapy-associated gastritis, Histopathology, 76, 531, 10.1111/his.14029 Maughan, 2017, Incidence of immune-related adverse events with program death receptor-1- and program death receptor-1 ligand-directed therapies in genitourinary cancers, Front Oncol., 7, 56, 10.3389/fonc.2017.00056 Naidoo, 2015, Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies, Ann. Oncol., 26, 2375, 10.1093/annonc/mdv383 Tang, 2019, Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors, Scand. J. Gastroenterol., 54, 538, 10.1080/00365521.2019.1594356 Weber, 2017, Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma, J. Clin. Oncol., 35, 785, 10.1200/JCO.2015.66.1389 Zander, 2016, Response to pembrolizumab in a patient with relapsing thymoma, J. Thorac. Oncol., 11, e147, 10.1016/j.jtho.2016.07.018